Machine learning classification can reduce false positives in structure-based virtual screening

Yusuf Adeshina

doi:10.1073/pnas.2000585117

2020-07-15

132

Yusuf Adeshina

Eric J. Deeds

John Karanicolas *

DOI：10.1073/pnas.2000585117

原文链接

查看原文

摘要

En 中文

With the recent explosion in the size of libraries available for screening, virtual screening is positioned to assume a more prominent role in early drug discovery's search for active chemical matter. In typical virtual screens, however, only about 12% of the top-scoring compounds actually show activity when tested in biochemical assays. We argue that most scoring functions used for this task have been developed with insufficient thoughtfulness into the datasets on which they are trained and tested, leading to overly simplistic models and/or overtraining. These problems are compounded in the literature because studies reporting new scoring methods have not validated their models prospectively within the same study. Here, we report a strategy for building a training dataset (D-COID) that aims to generate highly compelling decoy complexes that are individually matched to available active complexes. Using this dataset, we train a general-purpose classifier for virtual screening (vScreenML) that is built on the XGBoost framework. In retrospective benchmarks, our classifier shows outstanding performance relative to other scoring functions. In a prospective context, nearly all candidate inhibitors from a screen against acetylcholinesterase show detectable activity; beyond this, 10 of 23 compounds have IC50 better than 50 mu M. Without any medicinal chemistry optimization, the most potent hit has IC50 280 nM, corresponding to K-i of 173 nM. These results support using the D-COID strategy for training classifiers in other computational biology tasks, and for vScreenML in virtual screening campaigns against other protein targets. Both D-COID and vScreenML are freely distributed to facilitate such efforts.

Keyword:

virtual screening

machine learning classifier

structure-based drug design

protein-ligand complex